NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM 株式レポート

時価総額：US$128.5m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

NGM Biopharmaceuticals マネジメント

マネジメント 基準チェック /24

NGM Biopharmaceuticals'の CEO はDavid Woodhouseで、 Sep2018年に任命され、 の在任期間は 5.58年です。 の年間総報酬は$ 5.93Mで、 10.3%給与と89.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.14%を直接所有しており、その価値は$ 179.29K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と5.6年です。

主要情報

David Woodhouse

最高経営責任者

US$5.9m

報酬総額

CEO給与比率10.3%
CEO在任期間5.6yrs
CEOの所有権0.1%
経営陣の平均在職期間1.3yrs
取締役会の平均在任期間5.6yrs

経営陣の近況

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

CEO報酬分析

NGM Biopharmaceuticals の収益と比較して、David Woodhouse の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2023n/an/a

-US$142m

Sep 30 2023n/an/a

-US$151m

Jun 30 2023n/an/a

-US$170m

Mar 31 2023n/an/a

-US$178m

Dec 31 2022US$6mUS$610k

-US$163m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$135m

Mar 31 2022n/an/a

-US$125m

Dec 31 2021US$10mUS$580k

-US$120m

Sep 30 2021n/an/a

-US$121m

Jun 30 2021n/an/a

-US$122m

Mar 31 2021n/an/a

-US$111m

Dec 31 2020US$5mUS$525k

-US$102m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$490k

-US$43m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$4mUS$413k

-US$493k

報酬と市場: Davidの 総報酬 ($USD 5.93M ) は、 US市場 ($USD 667.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Woodhouse (52 yo)

5.6yrs

在職期間

US$5,933,500

報酬

Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Valerie Pierce
Senior VP4.5yrsUS$2.10m0.022%
$ 28.7k
Hsiao Lieu
Chief Medical Officer & Executive VP5.1yrsUS$2.73m0.017%
$ 22.3k
Jean Frederic Viret
Chief Financial Officer1.3yrsデータなしデータなし
Irene Perlich
VP, Corporate Controller & Principal Accounting Officerless than a yearデータなし0.011%
$ 13.8k
Daniel Kaplan
Chief Scientific Officer1.3yrsデータなしデータなし
Mahi Saraf
Director of People & Cultureless than a yearデータなしデータなし
Diana Bockus
Head of Business Development1.8yrsデータなしデータなし
Arthur Hsu
Senior Director & Head of Biology1.3yrsデータなしデータなし
Kara Calhoun
Senior Vice President of CMC & Process Developmentless than a yearデータなしデータなし

1.3yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: NGMの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Grant Heidrich
Special Advisorno dataデータなしデータなし
Arthur Levinson
Special Advisorno dataデータなしデータなし
David Goeddel
Lead Independent Director5.6yrsUS$270.23k19.87%
$ 25.5m
Michael Brown
Chairman of the Scientific Advisory Boardno dataデータなしデータなし
Joseph Goldstein
Member of the Scientific Advisory Boardno dataデータなしデータなし
Roger Perlmutter
Independent Director2.8yrsUS$250.00k0%
$ 0
Shelly Guyer
Independent Director4.3yrsUS$273.09k0%
$ 0
Robert Schreiber
Member of Scientific Advisory Boardno dataデータなしデータなし
Suzanne Hooper
Independent Director5.7yrsUS$265.00k0.0084%
$ 10.8k
Michael Fischbach
Member of Scientific Advisory Boardno dataデータなしデータなし

5.6yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: NGMの 取締役会 は 経験豊富 であると考えられます ( 5.6年の平均在任期間)。